Trastuzumab deruxtecan leads to longer overall survival than ramucirumab plus paclitaxel in HER2-positive gastric cancer
1. In this randomized controlled trial, among adults with HER2-positive unresectable or metastatic gastric cancer who had previously progressed on...










